Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals
Abstract
SARS-CoV-2 Omicron subvariants with increased transmissibility and immune evasion are spreading globally with alarming persistence. Whether the mutations and evolution of spike (S) Omicron subvariants alter the viral hijacking of human TMPRSS2 for viral entry remains to be elucidated. This is particularly important to investigate because of the large number and diversity of mutations of S Omicron subvariants reported since the emergence of BA.1. Here we report that human TMPRSS2 is a molecular determinant of viral entry for all the Omicron clinical isolates tested in human lung cells, including ancestral Omicron subvariants (BA.1, BA.2, BA.5), contemporary Omicron subvariants (BQ.1.1, XBB.1.5, EG.5.1) and currently circulating Omicron BA.2.86. First, we used a co-transfection assay to demonstrate the endoproteolytic cleavage by TMPRSS2 of spike Omicron subvariants. Second, we found that N-0385, a highly potent TMPRSS2 inhibitor, is a robust entry inhibitor of virus-like particles harbouring the S protein of Omicron subvariants. Third, we show that N-0385 exhibits nanomolar broad-spectrum antiviral activity against live Omicron subvariants in human Calu-3 lung cells and primary patient-derived bronchial epithelial cells. Interestingly, we found that N-0385 is 10-20 times more potent than the repositioned TMPRSS2 inhibitor, camostat, against BA.5, EG.5.1, and BA.2.86. We further found that N-0385 shows broad synergistic activity with clinically approved direct-acting antivirals (DAAs), i.e., remdesivir and nirmatrelvir, against Omicron subvariants, demonstrating the potential therapeutic benefits of a multi-targeted treatment based on N-0385 and DAAs.
Related
- Potent Antivirals for Respiratory Syncytial Virus Detected via Peptide-Based Fusion Inhibitor Screening
- Host-targeted repurposed diltiazem enhances the antiviral activity of direct acting antivirals against Influenza A virus and SARS-CoV-2
- Synergistic efficacy of the EGFR inhibitor osimertinib with the XPO1 inhibitor selinexor in T-cell acute lymphoblastic leukemia.
- NLRP3 inflammasome-driven inflammation as a cause of atrial fibrillation: potential synergistic inhibition of the NLRP3 via upstream magnesium repletion and targeting NLRP3 with a downstream inhibitor
- Synergistic Activity of Venetoclax and Rituximab in Multiply Relapsed or Refractory Waldenström Macroglobulinaemia
BibTeX
@article{perezvargas2026nanomolar,
title = {{Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals}},
author = {Jimena Pérez-Vargas and Gabriel Lemieux and Connor A.H. Thompson and Antoine Désilets and Siobhan Ennis and Guang Gao and Danielle Gordon and Annika Lea Schulz and Masahiro Niikura and Ivan Robert Nabi and Mel Krajden and Pierre-Luc Boudreault and Richard Leduc and François Jean},
journal = {Antiviral Research},
year = {2026},
month = oct,
doi = {10.1016/j.antiviral.2024.105869},
url = {https://hal.science/hal-05785152v1},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals
AU - Jimena Pérez-Vargas
AU - Gabriel Lemieux
AU - Connor A.H. Thompson
AU - Antoine Désilets
AU - Siobhan Ennis
AU - Guang Gao
AU - Danielle Gordon
AU - Annika Lea Schulz
AU - Masahiro Niikura
AU - Ivan Robert Nabi
AU - Mel Krajden
AU - Pierre-Luc Boudreault
AU - Richard Leduc
AU - François Jean
PY - 2026
DA - 2026/10/08
JO - Antiviral Research
DO - 10.1016/j.antiviral.2024.105869
UR - https://hal.science/hal-05785152v1
AB - SARS-CoV-2 Omicron subvariants with increased transmissibility and immune evasion are spreading globally with alarming persistence. Whether the mutations and evolution of spike (S) Omicron subvariants alter the viral hijacking of human TMPRSS2 for viral entry remains to be elucidated. This is particularly important to investigate because of the large number and diversity of mutations of S Omicron subvariants reported since the emergence of BA.1. Here we report that human TMPRSS2 is a molecular determinant of viral entry for all the Omicron clinical isolates tested in human lung cells, including ancestral Omicron subvariants (BA.1, BA.2, BA.5), contemporary Omicron subvariants (BQ.1.1, XBB.1.5, EG.5.1) and currently circulating Omicron BA.2.86. First, we used a co-transfection assay to demonstrate the endoproteolytic cleavage by TMPRSS2 of spike Omicron subvariants. Second, we found that N-0385, a highly potent TMPRSS2 inhibitor, is a robust entry inhibitor of virus-like particles harbouring the S protein of Omicron subvariants. Third, we show that N-0385 exhibits nanomolar broad-spectrum antiviral activity against live Omicron subvariants in human Calu-3 lung cells and primary patient-derived bronchial epithelial cells. Interestingly, we found that N-0385 is 10-20 times more potent than the repositioned TMPRSS2 inhibitor, camostat, against BA.5, EG.5.1, and BA.2.86. We further found that N-0385 shows broad synergistic activity with clinically approved direct-acting antivirals (DAAs), i.e., remdesivir and nirmatrelvir, against Omicron subvariants, demonstrating the potential therapeutic benefits of a multi-targeted treatment based on N-0385 and DAAs.
SN - 0166-3542
ER -